AM-Pharma Email Format
Biotechnology ResearchUtrecht, Netherlands11-50 Employees
AM-Pharma is a Dutch biotechnology company focused on developing therapies for serious medical conditions. Its lead candidate, ilofotase alfa, is being developed as an enzyme replacement therapy for adults with hypophosphatasia. The program focuses on addressing unmet medical needs in severe diseases. It is based in Utrecht, Netherlands, and operates within the biotechnology research sector. In September 2023, AM-Pharma appointed Juliane Bernholz as Chief Executive Officer, marking a notable leadership update.